Aileron Therapeutics Inc (ALRN) Earnings Report, Financial Results, Financial analysis

Aileron Therapeutics Inc increased first quarter of 2023 net loss per share of $-1.05 compare to net loss per share of $-0.09 recorded in the same quarter a year ago a decrease compare to $-0.05 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -1.05	$ 0 Mill
$-0.96	Unch.

Aileron Therapeutics Inc 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.

Aileron Therapeutics Inc is Expected to report next financial results on August 14, 2023.

More on ALRN's Income Statement

ALRN's NET INCOME

Aileron Therapeutics Inc 's in thefirst quarter of 2023 recorded net loss of $-4.779 million, an improvement compare to net loss of $-8.422 million in I. Quarter a year ago.

Sequentially net loss advanced

More on ALRN's Growth

Aileron Therapeutics Inc Inventories
ALRN's Cash flow In thefirst quarter of 2023 company's net cash flow was $3 million

Earnings quality

Aileron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Aileron Therapeutics Inc payed $ -4.78 cash per share, on a free-cash flow basis .

Book value grew by 1,432.84 % sequentially to $3.14 per share.
Tangible Book value grew to $ 3.14 per share from $ 0.21.

Company repurchased 86.28 million shares or 95.00 % in Mar 31 2023.

• More on ALRN's Dividends

Market Capitalization (Millions)	8
Shares Outstanding (Millions)	5
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-24
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	62

Earnings quality

Aileron Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Aileron Therapeutics Inc had negative $ -4.78 cash flow per share, on a free-cash flow basis .

Book value grew by 1,432.84 % sequentially to $3.14 per share.
Tangible Book value grew to $ 3.14 per share from $ 0.21.

Company repurchased 86.28 million shares or 95.00 % in Mar 31 2023.

• More on ALRN's Balance Sheets

Market Capitalization (Millions)	8
Shares Outstanding (Millions)	5
Total Debt (Millions $)	-
Revenue (TTM) (Millions $)	-
Net Income (TTM) (Millions $)	-24
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	62

Aileron Therapeutics Inc

ALRN's Financial Statements and Analysis